Cybin Secures Patent for CYB005 Program in Push for New CNS Disorder Treatments

LOS ANGELES- Cybin Inc., a neuropsychiatric biopharmaceutical company, announced that it has secured a U.S. patent (No. 12,122,741) covering the composition of matter for key molecules in its CYB005 program. This patent represents a strategic step for Cybin in developing non-hallucinogenic treatment options targeting central nervous system (CNS) disorders. The company’s CYB005 compounds, derived from the phenethylamine class, are being investigated for their ability to address mental health conditions by engaging serotonin 5-HT1A and 5-HT2C receptors—well-known targets in CNS therapeutic research.

In recent years, interest in non-psychedelic treatments within the psychedelics field has risen, as companies seek compounds that can yield therapeutic benefits without hallucinogenic effects. Doug Drysdale, Cybin’s CEO, highlighted that CYB005 supports the company’s commitment to innovative psychiatric treatments, complementing its main clinical-stage candidates, CYB003 and CYB004, which address major depressive disorder and generalized anxiety disorder respectively. The patent adds significant value to Cybin’s intellectual property portfolio, which also includes a recent publication detailing the development of CYB210010, a 5-HT2 receptor agonist, in the *Journal of Medicinal Chemistry*.

Cybin’s CYB005 initiative forms part of a broader push to develop CNS therapies without traditional psychedelics, positioning the company as a leading innovator in non-hallucinogenic mental health treatment options, with the goal of meeting substantial unmet clinical needs in psychiatry and neurology.